KIT and acute myeloid leukemia: Here, we report four children with AML with RUNX1::RUNX1T1 and KIT mutations, who mostly were refractory to demethylation drugs (HMAs) and donor lymphocyte infusion (DLI), who were treated with avapritinib as a preemptive intervention after allo-HSCT.